Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles

Nanomedicine

Volumn 5, Issue 6, 2010, Pages 867-879

  Murakami, Tatsuya ^a,b,c   Wijagkanalan, Wassana ^d   Hashida, Mitsuru ^c,d   Tsuchida, Kunihiro ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

apolipoprotein A I; doxorubicin; genetic engineering; intracellular drug delivery; nascent high density lipoprotein; protein transduction domain; TAT peptide

Indexed keywords

APOLIPOPROTEIN A1; DOXORUBICIN; HIGH DENSITY LIPOPROTEIN; NANOPARTICLE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CONFOCAL MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC ENGINEERING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT SCATTERING; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL;

DRUG DELIVERY SYSTEMS; HUMANS; LIPOPROTEINS, HDL; MICROSCOPY, CONFOCAL; NANOPARTICLES;

EID: 77956104719     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.66     Document Type: Article

References (33)

1. Linsel-Nitschke P, Tall AR: HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. 4, 193-206 (2005).
2. Glickson JD, Lund-Katz S, Zhou R et al.: Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents. Adv. Exp. Med. Biol. 645, 227-239 (2009).
3. Rensen PCN, de Vrueh RLA, Kuiper J et al.: Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv. Drug Delivery Rev. 47, 251-276 (2001).
4. Ishida T, Kiwada H: Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 354, 56-62 (2008).
5. Zheng G, Chen J, Li H et al.: Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc. Natl Acad. Sci. USA 102, 17757-17762 (2005).
6. Iovannisci DM, Beckstead JA, Ryan RO: Targeting nanodisks via a single chain variable antibody-apolipoprotein chimera. Biochem. Biophys. Res. Commun. 379, 466-469 (2009).
7. Nikanjam M, Blakely EA, Bjornstad KA et al.: Synthetic nano-low-density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int. J. Pharm. 328, 86-94 (2007).
8. Mishra VK, Anantharamaiah GM, Segrest JP et al.: Association of a model class A (Apolipoprotein) amphipathic a helical peptide with lipid. J. Biol. Chem. 281, 6511-6519 (2006).
9. Zhang Z, Cao W, Jin H et al.: Biomimetic nanocarrier for direct cytosolic drug delivery. Angew. Chem. Int. Ed. 48, 9171-9175 (2009).
10. Mulya A, Lee J-Y, Gebre AK et al.: Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. J. Lipid Res. 49, 2390-2401 (2008).
11. Lewis VO, Ozawa MG, Deavers MT et al.: The interleukin-11 receptor a as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples. Cancer Res. 69, 1995-1999 (2009).
12. Zurita AJ, Troncoso P, Cardo-Vila M et al.: Combinatorial screenings in patients: the interleukin-11 receptor a as a candidate target in the progression of human prostate cancer. Cancer Res. 64, 435-439 (2004).
13. Vives E: Present and future of cell-penetrating peptide mediated delivery systems: "is the Trojan horse too wild to go only to Troy?" J. Control. Release 109, 77-85 (2005).
14. Snyder EL, Saenz CC, Denicourt C et al.: Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res. 65, 10646-10650 (2005).
15. Meade BR, Dowdy SF: Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv. Drug Delivery Rev. 60, 530-536 (2008).
16. Han H, Sasaki J, Matsunaga A et al.: A novel mutant, ApoA-I Nichinan (Glu235-0), is associated with low HDL cholesterol levels and decreased cholesterol efflux from cells. Arterioscler. Thromb. Vasc. Biol. 19, 1447-1455 (1999).
17. Rogers DP, Brouillette CG, Engler JA et al.: Truncation of the amino terminus of human apolipoprotein A-I substantially alters only the lipid-free conformation. Biochemistry 36, 288-300 (1997).
18. Hara I, Okazaki M: High-performance liquid chromatography of serum lipoproteins. In: Methods Enzymol. Warnick GR (Ed.). Academic Press, Inc., Orlando, FL, USA, 57-78, 129 (1986).
19. Kader A, Pater A: Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J. Control. Release 80, 29-44 (2002).
20. Brouillette CG, Anantharamaiah GM, Engler JA et al.: Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim. Biophys. Acta 1531, 4-46 (2001).
21. Massey JB, Pownall HJ: Cholesterol is a determinant of the structure of discoidal high-density lipoproteins formed by the solubilization of phospholipid membranes by apolipoprotein A-I. Biochim. Biophys. Acta 1781, 245-253 (2008).
22. Murakami T, Sawada H, Tamura G et al.: Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy. Nanomed. 3, 453-463 (2008).
23. Liadaki KN, Liu T, Xu S et al.: Binding of high-density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. J. Biol. Chem. 275, 21262-21271 (2000).
24. Williams DL, de la Llera-Moya M, Thuahnai ST et al.: Binding and cross-linking studies show that scavenger receptor BI interacts with multiple sites in apolipoprotein A-I and identify the class A amphipathic a-helix as a recognition motif. J. Biol. Chem. 275, 18897-18904 (2000).
25. Corbin IR, Chen J, Cao W et al.: Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers. J. Biomed. Nanotech. 3, 367-376 (2007).
26. Murakami T, Tsuchida K, Hashida M et al.: Size control of lipid-based drug carriers by drug loading. Mol. BioSyst. 6, 789-791 (2010).
27. Shen F, Chu S, Benca AK et al.: Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J. Pharmacol. Exp. Ther. 324, 95-102 (2008).
28. Tseng Y-L, Liu J-J, Hong R-L: Translocation of liposomes into cancer cells by cell penetrating peptides penetratin and Tat: a kinetic and efficacy study. Mol. Pharmacol. 62, 864-872 (2002).
29. Ishida T, Okada Y, Kobayashi T et al.: Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. Int. J. Pharm. 309, 94-100 (2006).
30. Fretz MM, Koning GA, Mastrobattista E et al.: OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochim. Biophys. Acta 1665, 48-56 (2004).
31. Ma K, Hu M-X, Qi Y et al.: PAMAM-triamcinolon acetonide conjugate as a nucleus-targeting gene carrier for enhanced transfer activity. Biomaterials 30, 6109-6118 (2009).
32. Mukhopadhyay P, Rajesh M, Batkai S et al.: Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am. J. Physiol. Heart Circ. Physiol. 296, H1466-H1483 (2009).
33. Abraham SA, Waterhouse DN, Mayer LD et al.: The liposomal formulation of doxorubicin. In: Methods Enzymol. Duzgunes N (Ed.), Academic Press, Inc., Orland, FL, USA 71-97, 391 (2005).